BPTSY vs. APVO, GRTX, BPTH, ONCT, SLRX, ADXS, VAXX, PTEIQ, ASLN, and PBLA
Should you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Aptevo Therapeutics (APVO), Galera Therapeutics (GRTX), Bio-Path (BPTH), Oncternal Therapeutics (ONCT), Salarius Pharmaceuticals (SLRX), Ayala Pharmaceuticals (ADXS), Vaxxinity (VAXX), PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), and Panbela Therapeutics (PBLA). These companies are all part of the "pharmaceutical products" industry.
Biophytis vs. Its Competitors
Aptevo Therapeutics (NASDAQ:APVO) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment.
Biophytis has lower revenue, but higher earnings than Aptevo Therapeutics.
In the previous week, Aptevo Therapeutics had 2 more articles in the media than Biophytis. MarketBeat recorded 3 mentions for Aptevo Therapeutics and 1 mentions for Biophytis. Aptevo Therapeutics' average media sentiment score of 0.72 beat Biophytis' score of -1.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.
Aptevo Therapeutics presently has a consensus target price of $219,040.00, indicating a potential upside of 4,989,421.64%. Given Aptevo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aptevo Therapeutics is more favorable than Biophytis.
8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 0.0% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Biophytis' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.
Aptevo Therapeutics received 199 more outperform votes than Biophytis when rated by MarketBeat users.
Aptevo Therapeutics has a beta of 5.75, indicating that its stock price is 475% more volatile than the S&P 500. Comparatively, Biophytis has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Summary
Aptevo Therapeutics beats Biophytis on 9 of the 13 factors compared between the two stocks.
Get Biophytis News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BPTSY vs. The Competition
Biophytis Competitors List
Related Companies and Tools
This page (NASDAQ:BPTSY) was last updated on 6/14/2025 by MarketBeat.com Staff
